These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38730340)

  • 1. Determination of birth prevalence of sickle cell disease using point of care test HemotypeSC™ at Rundu Hospital, Namibia.
    Mano RM; Kuona P; Misihairabgwi JM
    BMC Pediatr; 2024 May; 24(1):323. PubMed ID: 38730340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of point of care tests for newborn screening for sickle cell disease: Evaluation of HemotypeSC™ and sickle SCAN® in Tanzania.
    Christopher H; Josephat E; Kaywanga F; Saul S; Mshana I; Kunambi P; Nasser A; Chamba C; Makani J; Nkya S
    Int J Lab Hematol; 2022 Oct; 44(5):959-965. PubMed ID: 35775883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extremely high birth prevalence of sickle cell disease in rural Tanzania.
    Eastburg L; Peckham A; Kawira E; Chirangi B; Adler D; Akungo BD; Smart LR; Ambrose EE
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28620. PubMed ID: 32803850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.
    Steele C; Sinski A; Asibey J; Hardy-Dessources MD; Elana G; Brennan C; Odame I; Hoppe C; Geisberg M; Serrao E; Quinn CT
    Am J Hematol; 2019 Jan; 94(1):39-45. PubMed ID: 30290004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening.
    Kunz JB; Awad S; Happich M; Muckenthaler L; Lindner M; Gramer G; Okun JG; Hoffmann GF; Bruckner T; Muckenthaler MU; Kulozik AE
    Ann Hematol; 2016 Feb; 95(3):397-402. PubMed ID: 26658910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study.
    Nnodu OE; Sopekan A; Nnebe-Agumadu U; Ohiaeri C; Adeniran A; Shedul G; Isa HA; Owolabi O; Chianumba RI; Tanko Y; Iyobosa JH; Adekile AD; Olopade OI; Piel FB
    Lancet Haematol; 2020 Jul; 7(7):e534-e540. PubMed ID: 32589979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease: Promises and challenges.
    Nnodu O; Isa H; Nwegbu M; Ohiaeri C; Adegoke S; Chianumba R; Ugwu N; Brown B; Olaniyi J; Okocha E; Lawson J; Hassan AA; Diaku-Akinwumi I; Madu A; Ezenwosu O; Tanko Y; Kangiwa U; Girei A; Israel-Aina Y; Ladu A; Egbuzu P; Abjah U; Okolo A; Akbulut-Jeradi N; Fernandez M; Piel FB; Adekile A
    Blood Cells Mol Dis; 2019 Sep; 78():22-28. PubMed ID: 30773433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting.
    Alvarez OA; Hustace T; Voltaire M; Mantero A; Liberus U; Saint Fleur R
    Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31530717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saving lives through early diagnosis: the promise and role of point of care testing for sickle cell disease.
    Dexter D; McGann PT
    Br J Haematol; 2022 Jan; 196(1):63-69. PubMed ID: 34340260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening for sickle cell disease: an innovative pilot program to improve child survival in Dar es Salaam, Tanzania.
    Nkya S; Mtei L; Soka D; Mdai V; Mwakale PB; Mrosso P; Mchoropa I; Rwezaula S; Azayo M; Ulenga N; Ngido M; Cox SE; D'Mello BS; Masanja H; Kabadi GS; Mbuya F; Mmbando B; Daniel Y; Streetly A; Killewo J; Tluway F; Lyimo M; Makani J
    Int Health; 2019 Nov; 11(6):589-595. PubMed ID: 31145786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a multicenter universal newborn screening program for sickle cell disease in Italy: A call to action.
    Colombatti R; Martella M; Cattaneo L; Viola G; Cappellari A; Bergamo C; Azzena S; Schiavon S; Baraldi E; Dalla Barba B; Trafojer U; Corti P; Uggeri M; Tagliabue PE; Zorloni C; Bracchi M; Biondi A; Basso G; Masera N; Sainati L
    Pediatr Blood Cancer; 2019 May; 66(5):e27657. PubMed ID: 30724025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnosis of sickle cell disease at birth hospitals and vaccination centers in Angola using point-of-care tests.
    Olaniyan HS; Briscoe C; Muhongo M; Pascoal R; Armando A; Santos B; McGann PT
    Blood Adv; 2023 Oct; 7(19):5860-5867. PubMed ID: 37399450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for a large-scale newborn screening strategy for sickle cell disease in Mali: A comparative diagnostic performance study of two rapid diagnostic tests (SickleScan® and HemotypeSC®) on cord blood.
    Guindo A; Cisse Z; Keita I; Desmonde S; Sarro YDS; Touré BA; Baraika MA; Tessougué O; Guindo P; Coulibaly M; Traore O; Sylla N; Diassana M; Saye A; Picot V; Lauressergues E; Leroy V
    Br J Haematol; 2024 Jan; 204(1):337-345. PubMed ID: 37728227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn screening for sickle cell disease in Kisangani, Democratic Republic of the Congo: an update.
    Kasai ET; Gulbis B; Ntukamunda JK; Bours V; Batina Agasa S; Marini Djang'eing'a R; Boemer F; Katenga Bosunga G; Ngbonda Dauly N; Sokoni Vutseme J; Boso Mokili B; Alworong'a Opara JP
    Hematology; 2023 Dec; 28(1):2213043. PubMed ID: 37183964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle SCAN™ (BioMedomics) fulfills analytical conditions for neonatal screening of sickle cell disease.
    Nguyen-Khoa T; Mine L; Allaf B; Ribeil JA; Remus C; Stanislas A; Gauthereau V; Enouz S; Kim JS; Yang X; Gluckman E; Beaudeux JL; Munnich A; Girot R; Cavazzana M
    Ann Biol Clin (Paris); 2018 Aug; 76(4):416-420. PubMed ID: 29976532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019.
    Hernandez AG; Kiyaga C; Howard TA; Ssewanyana I; Ndeezi G; Aceng JR; Ware RE
    Trop Med Int Health; 2021 Jan; 26(1):23-32. PubMed ID: 33151598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study.
    Oluwole EO; Adeyemo TA; Osanyin GE; Odukoya OO; Kanki PJ; Afolabi BB
    PLoS One; 2020; 15(12):e0242861. PubMed ID: 33270733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Newborn screening for sickle cell disease in France].
    Brousse V; Allaf B; Benkerrou M
    Med Sci (Paris); 2021 May; 37(5):482-490. PubMed ID: 34003094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study.
    Tubman VN; Marshall R; Jallah W; Guo D; Ma C; Ohene-Frempong K; London WB; Heeney MM
    Pediatr Blood Cancer; 2016 Apr; 63(4):671-6. PubMed ID: 26739520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point-of-Care Newborn Screening for Sickle Cell Disease at Selected Health Facilities in the Gambia.
    Adegoke SA; Makalo L; Sallah A; Saine H; Joof S; Conteh A; Bah R; Camara Jammeh AF; Bass M; Jallow M; Nnodu OE
    Hemoglobin; 2024 May; 48(3):169-174. PubMed ID: 38980121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.